TS
PAND

Thomas Steyer’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

Thomas Steyer’s Portfolio PAND Stock Details PAND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-100,000
Closed -$1.15M – 160
2020
Q3 		$1.15M Buy
+100,000
New +$1.71M 0.01% 121

Other funds holding PAND

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Thomas Steyer's PAND Position: Q4 2020 in Review

Thomas Steyer sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q4 2020, closing a stake of 100,000 shares — an estimated $1.15M sold.

Thomas Steyer first reported a position in PAND in Q3 2020 and held it in 1 quarter. The position peaked at $1.15M in Q3 2020. 48 funds tracked by Wall St. Rank hold PAND as of Q4 2020.

  • Thomas Steyer reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Thomas Steyer sold 100,000 Pandion Therapeutics Inc. Common Stock shares in Q4 2020, an estimated $1.15M.
  • Thomas Steyer first reported a position in Pandion Therapeutics Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Thomas Steyer's Pandion Therapeutics Inc. Common Stock position peaked at $1.15M in Q3 2020.
  • 48 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q4 2020.

Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.